Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ZSP1273 in Elderly Participants
NCT06157450Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of anlatrelvir in Influenza A (IAV) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to infinity and 1 more. Started Oct 2023; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT06157450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157450.